Triple-negative breast cancer does not respond to targeted breast cancer treatments, which limits treatment to primarily ...
The results could pave the way for Datroway to supplant chemotherapy in certain triple-negative tumors, adding to existing ...
Race does not significantly impact tumor mutations of triple-negative breast cancer, suggesting genetics and environmental ...
Datroway significantly improves overall and progression-free survival in metastatic triple-negative breast cancer patients ineligible for immunotherapy. TROPION-Breast02 trial results highlight ...
Positive topline results from the TROPION-Breast02 phase 3 trial showed DATROWAY® (datopotamab deruxtecan) demonstrated a ...
The TROPION-Breast02 trial is the first to show overall survival benefit in this patient population, indicating a potential ...
Care for HER supports black breast cancer patients whose outcomes are much worse. Black women are 40% more likely to die of ...
Laura Irvin, a nurse from New Madrid, Mo., shares how battling a breast cancer diagnosis at age 34 prepared her to be a ...
From left to right, Dr. Fernando Lecanda, Dr. Karmele Valencia, and Dr. Rafael Martínez Monge, from the Adhesion and Metastasis group at Cima, with Dr. Borja Ruiz-Fernández de Córdoba, also author of ...
Triple Negative Breast Cancer (TNBC) is one of the most aggresive types of breast cancer. It’s the kind of breast cancer that doesn’t have estrogen receptors, progesterone receptors, and human ...
AstraZeneca and Daiichi Sankyo's Datroway improved survival outcomes over chemotherapy in advanced triple-negative breast ...
FLORHAM PARK, N.J. and LONDON and CHARLOTTESVILLE, Va., Sept (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (“Cellectar”) (NASDAQ: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback